Hormonal
Tirzepatide use is associated with novel safety signals including belching, upper respiratory tract infections, and postmenopausal hemorrhage, which are not prominently featured in standard prescribing information.
Be aware that Tirzepatide may be linked to new symptoms not always listed in official documents, such as excessive belching, respiratory infections, or unusual bleeding (especially in postmenopausal women). Report these to your healthcare provider, as they are emerging safety signals.
Novel signals included upper respiratory infections and postmenopausal hemorrhage... Belching... exhibited the strongest signal strengths.
Why this rating
FAERS data is spontaneous reporting; causality is not established, and sample sizes for these specific events are small.
Source
Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
Zhenpo Zhang et al. · Endocrine Connections · 2025
DOI 10.1530/ec-25-0205
More from this paper
- Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.Moderate
- Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →